Prevalere Life Sciences, Inc. (ICON Development Solutions)
For over 20 years, Prevalere Life Sciences has provided analytical testing services to meet the research and development challenges of the pharmaceutical and biotechnology industries. Operating from a GLP/cGMP compliant facility, which houses 7 laboratories in Whitesboro, New York, Prevalere offers bioanalytical services for large and small molecules in support of pre-clinical toxicology and Phase I through Phase IV clinical trials.
For small molecules, Prevalere offers method development, assay validation, and specimen analysis using state-of-the-art mass spectrometry (LC/MS/MS). Prevalere has a specially designed hazardous sample laboratory for the analysis of HIV-positive specimens, hepatitis-B infected specimens and potential carcinogensâ with all hazardous samples handled by specially trained scientists.
Prevalere also develops sensitive and specific immunoassays for the research and development of macromolecules supporting PK, immunogenicity and biomarker studies. The analytical techniques currently offered at Prevalere are ELISAs, the most widespread solid phase immunoassay format. Direct, indirect, capture and competitive ELISA formats are available, and the platforms include absorbance, chemiluminescence and electrochemiluminescence using MSD technology. Prevalere also provides high throughput ELISA support for drug development using assay formats developed internally or provided by the client.
In support of these GLP services, Prevalere offers data analysis, pharmacokinetic/pharmacodynamic modeling and technical writing services to the pharmaceutical industry.
Prevalere offers a full suite of comprehensive cGMP compliant services to determine the chemical structure and purity of various compounds. Chemical analysis capabilities include Mass Spectrometry (LC/MS/MS, GC/MS, DEP/MS, ESI/MS), Physical Analysis (X-Ray Powder Diffraction, TGA/FTIR), as well as Quantitative Analysis (Elemental Microanalysis, Karl Fischer Moisture Analysis, Atomic Absorption, & USP Testing).
All of Prevalereâs procedures are geared toward meeting clientsâ tightest of timelines in a cost-effective manner. Electronic transmission of data and âreal-timeâ QA auditing of analytical results are a few of the tools used to keep drug development efforts on track.
For more information, please go to:
